HIGHLIGHTS
- who: Stefania Napolitano from the Napoli, Italy Innsbruck Medical University, Austria have published the paper: CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients, in the Journal: (JOURNAL) of 10/05/2022
- what: The aim of the study is to evaluate the efficacy (in terms of OS) of avelumab and cetuximab combined in pretreated RAS, BRAF WT mCRC patients compared to cetuximab alone. Subjects who discontinue the trial treatment for reasons other than . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.